pivalyloxymethyl butyrate has been researched along with formaldehyde in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cutts, SM; Hmelnitsky, I; Nudelman, A; Phillips, DR; Rephaeli, A | 1 |
| Cutts, SM; Nudelman, A; Phillips, DR; Rephaeli, A; Swift, LP | 1 |
| Cutts, SM; Levovich, I; Nudelman, A; Phillips, DR; Pillay, V; Rephaeli, A; Spencer, DM | 1 |
3 other study(ies) available for pivalyloxymethyl butyrate and formaldehyde
| Article | Year |
|---|---|
Molecular basis for the synergistic interaction of adriamycin with the formaldehyde-releasing prodrug pivaloyloxymethyl butyrate (AN-9).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Breast Neoplasms; Butyrates; DNA Adducts; Doxorubicin; Drug Administration Schedule; Drug Synergism; Formaldehyde; Humans; Neuroblastoma; Prodrugs; Tumor Cells, Cultured | 2001 |
Sequence specificity of adriamycin-DNA adducts in human tumor cells.
Topics: Antibiotics, Antineoplastic; Base Sequence; Butyrates; DNA; DNA Adducts; Doxorubicin; Formaldehyde; Humans; Molecular Sequence Data; Neoplasms; Tumor Cells, Cultured | 2003 |
Formaldehyde-releasing prodrugs in combination with adriamycin can overcome cellular drug resistance.
Topics: Antineoplastic Agents; Butyrates; Cell Line, Tumor; Cell Survival; DNA Adducts; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Formaldehyde; Humans; Inhibitory Concentration 50; Molecular Structure; Prodrugs; Topoisomerase II Inhibitors | 2005 |